The Food and Drug Administration on Monday said popular GLP-1 weight-loss medications such as Ozempic, Wegovy and others must put a warning about greater risks for permanent vision loss on their packaging.
The federal agency’s requirement also extends to Mounjaro, Zepbound and Soliqua, with the FDA saying the drugs have links to causing nonarteritic anterior ischemic optic neuropathy, or NAION.
The condition reduces blood flow to the optic nerve, causing sudden vision loss in one eye. There is no known treatment to reverse the vision loss.
People were interested in these podcasts
Please read our comment policy before commenting.